Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2007

01-10-2007 | Original Paper

Pharmacokinetics of Cyclosporine A After Massive Hepatectomy: A Hint for Small-for-Size Graft in Living Donor Liver Transplantation

Authors: Hisamitsu Shinohara, Mitsuo Shimada, Takashi Ogasawara, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Masahiko Fujii

Published in: Digestive Diseases and Sciences | Issue 10/2007

Login to get access

Abstract

In living donor liver transplantation, graft size is very important, and various studies have been conducted regarding these problems in small-for-size (SFS) grafts. The administration of immunosuppressants for SFS graft, in which the functional liver mass is small and necessary for excessive liver regeneration, has not been reported so far. The aims of this study were to investigate the optimal administration of cyclosporine (CyA) and characteristics of metabolism of CyA, according to liver volume. Seven-week-old male Wister rats were randomly divided into four groups: two CyA-administered groups (CyA groups), 70% and 90% hepatectomy (Hx); and two control groups, 70% and 90% Hx. The 70% Hx and 90% Hx were used as the surrogate model of SFS for 30% and 10% graft models. In CyA groups, CyA (5 mg/kg/day) was given for 3 days before Hx and after surgery until sacrifice. Animals were sacrificed at 0, 12, 24, 48, and 72 hr after Hx. The blood concentration of CyA and the expression of the CYP3A2 gene were measured at each point in CyA groups, and liver regeneration was evaluated by measuring the ratio of remnant liver weight to body weight in each group. Regarding the blood concentration of CyA, no difference was recognized between 30% and 10% graft models except for 72 hr after Hx. As for liver regeneration, no significant difference was recognized. Regarding the expression of CYP3A2, no change was noted in the 30% graft model; on the other hand, CYP3A2 expression was reduced. Significant differences between the 30% and the 10% graft model were observed 48 and 72 hr after Hx. The blood concentration of CyA was not dependent on the volume of the liver graft.
Literature
1.
go back to reference Kiuch T, Kawasaki M, Uryuhara K, Inoue Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K (1999) Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 67:321–327CrossRef Kiuch T, Kawasaki M, Uryuhara K, Inoue Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K (1999) Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 67:321–327CrossRef
2.
go back to reference Sugawara Y, Makuuchi M, Takayama T, Imamura H, Dowaki S, Mizuta K, Kawarasaki H, Hashizume K (2001) Small-for-size grafts in living related liver transplantation. J Am Coll Surg 192(4):510–513PubMedCrossRef Sugawara Y, Makuuchi M, Takayama T, Imamura H, Dowaki S, Mizuta K, Kawarasaki H, Hashizume K (2001) Small-for-size grafts in living related liver transplantation. J Am Coll Surg 192(4):510–513PubMedCrossRef
3.
go back to reference Shimada M, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, Yoshizumi T, Soejima Y, Suehiro T, Maehara Y (2004) Is graft size a major risk factor in living-donor adult liver transplantation? Transpl Int 17(6):310–316PubMedCrossRef Shimada M, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, Yoshizumi T, Soejima Y, Suehiro T, Maehara Y (2004) Is graft size a major risk factor in living-donor adult liver transplantation? Transpl Int 17(6):310–316PubMedCrossRef
4.
go back to reference Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G (1999) Peak cyclospoline levels (Cmax) correlate with freedom from liver graft rejection: result of a prospective, randomized comparison of neural and sandimmune for liver transplantation (NOF-8). Transplantation 67(8):1133–1137PubMedCrossRef Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G (1999) Peak cyclospoline levels (Cmax) correlate with freedom from liver graft rejection: result of a prospective, randomized comparison of neural and sandimmune for liver transplantation (NOF-8). Transplantation 67(8):1133–1137PubMedCrossRef
5.
go back to reference Fukudo M, Yano I, Masuda S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2006) Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplantation patient: twice daily vs. once daily dosing. Liver Transpl 12(2):292–300PubMedCrossRef Fukudo M, Yano I, Masuda S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2006) Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplantation patient: twice daily vs. once daily dosing. Liver Transpl 12(2):292–300PubMedCrossRef
6.
go back to reference Fukudo M, Yano I, Masuda S, Fukatsu S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2005) Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplantation patient. Clin Pharmacol Ther 78(2):168–181PubMedCrossRef Fukudo M, Yano I, Masuda S, Fukatsu S, Katura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K (2005) Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplantation patient. Clin Pharmacol Ther 78(2):168–181PubMedCrossRef
7.
go back to reference Molpeceres J, Chacon M, Guzman M, Aberturas MR, Berges L (2000) Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rat after a single intravenous dose. Int J Pharm 197(1–2):129–141PubMedCrossRef Molpeceres J, Chacon M, Guzman M, Aberturas MR, Berges L (2000) Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rat after a single intravenous dose. Int J Pharm 197(1–2):129–141PubMedCrossRef
8.
go back to reference Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K (2002) Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporine A disposition kinetics by dexamethasone. Biochem Pharmacol 63(4):777–783PubMedCrossRef Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K (2002) Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporine A disposition kinetics by dexamethasone. Biochem Pharmacol 63(4):777–783PubMedCrossRef
9.
go back to reference Uwe C, Karl-Friendrich S (1995) Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 28:547–559CrossRef Uwe C, Karl-Friendrich S (1995) Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 28:547–559CrossRef
10.
go back to reference Tomlinson ES, JMaggs JL, Park BK, Back DJ (1997) Dexamethasone metabolism in vitro: species difference. J Steroid Biochem Mol Biol 62:345–352PubMedCrossRef Tomlinson ES, JMaggs JL, Park BK, Back DJ (1997) Dexamethasone metabolism in vitro: species difference. J Steroid Biochem Mol Biol 62:345–352PubMedCrossRef
11.
go back to reference Dahmen U, Gu YL, Shen K, Dirsch O, Li J, Fan LM, Broelsch CE (2002) Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. Transplant Proc 34(6):2312–2313PubMedCrossRef Dahmen U, Gu YL, Shen K, Dirsch O, Li J, Fan LM, Broelsch CE (2002) Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. Transplant Proc 34(6):2312–2313PubMedCrossRef
12.
go back to reference Morii Y, Kawano K, Kim YI, Aramaki M, Yoshida T, Kitano S (1999) Augmentative effect of cyclosporine A on rat liver regeneration: influence on hepatocyte growth factor and transforming growth factor-β1. Eur Surg Res 31(5):399–405PubMedCrossRef Morii Y, Kawano K, Kim YI, Aramaki M, Yoshida T, Kitano S (1999) Augmentative effect of cyclosporine A on rat liver regeneration: influence on hepatocyte growth factor and transforming growth factor-β1. Eur Surg Res 31(5):399–405PubMedCrossRef
13.
go back to reference Higgins GM, Anderson RM (1931) Experimental pathology of the liver. Arch Pathol 12:186–202 Higgins GM, Anderson RM (1931) Experimental pathology of the liver. Arch Pathol 12:186–202
14.
go back to reference Carson E, Rioux N, Nicolas O, Lebel-Talbot H, Bettina A (2005) Hamelin: quantification of expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-RCR. J Biochem Mol Toxicol 19(6):368–378CrossRef Carson E, Rioux N, Nicolas O, Lebel-Talbot H, Bettina A (2005) Hamelin: quantification of expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT-RCR. J Biochem Mol Toxicol 19(6):368–378CrossRef
15.
go back to reference Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623–653PubMedCrossRef Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623–653PubMedCrossRef
16.
go back to reference Ptachcinski RJ, Venkataramanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 11:107–132PubMedCrossRef Ptachcinski RJ, Venkataramanan R, Burckart GJ (1986) Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 11:107–132PubMedCrossRef
17.
go back to reference Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K (2005) Long-term levotyroxine treatment decreases the oral bioavailability of cyclosporine A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet 20(5):324–330PubMedCrossRef Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K (2005) Long-term levotyroxine treatment decreases the oral bioavailability of cyclosporine A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet 20(5):324–330PubMedCrossRef
Metadata
Title
Pharmacokinetics of Cyclosporine A After Massive Hepatectomy: A Hint for Small-for-Size Graft in Living Donor Liver Transplantation
Authors
Hisamitsu Shinohara
Mitsuo Shimada
Takashi Ogasawara
Yuji Morine
Tetsuya Ikemoto
Satoru Imura
Masahiko Fujii
Publication date
01-10-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9744-1

Other articles of this Issue 10/2007

Digestive Diseases and Sciences 10/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine